FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry and provides the use of sulphated hyaluronic acid for topical application for the prevention and / or treatment of herpes simplex labialis and herpes genitalis, vesicular stomatitis virus and cytomegalovirus, said sulphated hyaluronic acid (HA) having a molecular weight in the range of 10,000 to 50,000 Da, from 150,000 to 250,000 Da or from 500,000 to 750,000 Da and a degree of sulphation equal to 1 or 3.
EFFECT: invention provides high activity against herpes simplex labialis and herpes genitalis, vesicular stomatitis virus and cytomegalovirus.
7 cl, 15 dwg, 4 tbl, 32 ex
